Techne Corporation  

(Public, NASDAQ:TECH)   Watch this stock  
Find more results for Howard Blood
95.52
+0.46 (0.48%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 95.08 - 96.11
52 week 75.43 - 97.15
Open 95.49
Vol / Avg. 109,382.00/136,845.00
Mkt cap 3.53B
P/E 31.91
Div/yield 0.31/1.30
EPS 2.99
Shares 37.00M
Beta 0.63
Inst. own 97%
Oct 27, 2014
Q1 2015 Techne Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 4, 2014
Techne Corp at Robert W. Baird & Co. Inc Health Care Conference - 9:40AM EDT - Add to calendar
Aug 11, 2014
Q4 2014 Techne Corp Earnings Release
Aug 11, 2014
Q4 2014 Techne Corp Earnings Call
Jun 10, 2014
Techne Corp at William Blair & Company LLC Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin 28.99% 31.01%
Operating margin 41.99% 44.65%
EBITD margin - 46.06%
Return on average assets 12.71% 13.53%
Return on average equity 13.69% 14.48%
Employees 789 -
CDP Score - -

Address

614 Mckinley Pl NE
MINNEAPOLIS, MN 55413-2610
United States - Map
+1-612-3792956 (Phone)
+1-612-6564400 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TECHNE Corporation, is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), Boston Biochem, Inc. (Boston Biochem), and BiosPacific, Inc. (BiosPacific). The Company operates in two segments: biotechnology and hematology. The Company's biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company's hematology reporting segment, which consists of R&D Systems' Hematology Division, develops and manufactures hematology controls and calibrators for sale worldwide. In July 2014, TECHNE Corporation acquired Novus Biologicals. Effective August 1, 2014,TECHNE Corporation acquired of ProteinSimple.

Officers and directors

Robert V. Baumgartner CPA Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Charles R. Kummeth President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Independent Vice Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
James T. Hippel Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
David Eansor Senior Vice President - Novus Biologicals
Age: 53
Bio & Compensation  - Reuters
Kevin Reagan Senior Vice President - Biotech
Age: 61
Bio & Compensation  - Reuters
Marcel Veronneau Senior Vice President - Clinical Controls
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
J. Fernando Bazan Ph.D. Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Howard V. O'Connell Lead Independent Director
Age: 83
Bio & Compensation  - Reuters
Harold J. Wiens Director
Age: 68
Bio & Compensation  - Reuters